1. Home
  2. RARE vs PAM Comparison

RARE vs PAM Comparison

Compare RARE & PAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RARE
  • PAM
  • Stock Information
  • Founded
  • RARE 2010
  • PAM 1945
  • Country
  • RARE United States
  • PAM Argentina
  • Employees
  • RARE N/A
  • PAM N/A
  • Industry
  • RARE Biotechnology: Pharmaceutical Preparations
  • PAM Electric Utilities: Central
  • Sector
  • RARE Health Care
  • PAM Utilities
  • Exchange
  • RARE Nasdaq
  • PAM Nasdaq
  • Market Cap
  • RARE 5.2B
  • PAM 4.8B
  • IPO Year
  • RARE 2014
  • PAM N/A
  • Fundamental
  • Price
  • RARE $43.98
  • PAM $85.81
  • Analyst Decision
  • RARE Strong Buy
  • PAM Buy
  • Analyst Count
  • RARE 14
  • PAM 4
  • Target Price
  • RARE $88.43
  • PAM $58.75
  • AVG Volume (30 Days)
  • RARE 717.6K
  • PAM 305.8K
  • Earning Date
  • RARE 02-13-2025
  • PAM 11-06-2024
  • Dividend Yield
  • RARE N/A
  • PAM N/A
  • EPS Growth
  • RARE N/A
  • PAM 166.38
  • EPS
  • RARE N/A
  • PAM 0.47
  • Revenue
  • RARE $522,745,000.00
  • PAM $2,709,042,561.00
  • Revenue This Year
  • RARE $27.36
  • PAM $114,496.88
  • Revenue Next Year
  • RARE $18.61
  • PAM $40.83
  • P/E Ratio
  • RARE N/A
  • PAM $8.32
  • Revenue Growth
  • RARE 27.44
  • PAM 221.02
  • 52 Week Low
  • RARE $37.02
  • PAM $38.15
  • 52 Week High
  • RARE $60.37
  • PAM $93.11
  • Technical
  • Relative Strength Index (RSI)
  • RARE 33.50
  • PAM 55.49
  • Support Level
  • RARE $41.45
  • PAM $88.43
  • Resistance Level
  • RARE $50.00
  • PAM $93.11
  • Average True Range (ATR)
  • RARE 1.83
  • PAM 3.96
  • MACD
  • RARE -0.31
  • PAM -0.98
  • Stochastic Oscillator
  • RARE 26.55
  • PAM 32.67

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

About PAM Pampa Energia S.A.

Pampa Energia SA and its subsidiaries are engaged in the Energy business. The operating business segments of the firm are Electricity generation, Electricity distribution, Oil and Gas, Petrochemicals, and Holding and other business. The company derives the maximum revenue from the Distribution of energy.

Share on Social Networks: